|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Ra Pharmaceuticals, Inc. (RARX) |
|
|
$46.96 0.00 (0.00%) as of 4:30 Thu 3/19
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,150,000 |
Market
Cap: |
2.21(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$46.96 - $46.96 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
King John C |
Chief Commercial Officer |
|
2019-04-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,329 |
15,329 |
|
- |
|
Ricardo Alonso |
See RemarksOfficer |
|
2019-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,285 |
|
- |
|
Lubner David Charles |
Executive V.P. & CFO |
|
2019-02-01 |
4 |
D |
$21.00 |
$69,111 |
D/D |
(3,291) |
7,126 |
|
- |
|
Lubner David Charles |
Executive V.P. & CFO |
|
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,417 |
10,417 |
|
- |
|
Farzaneh-Far Ramin |
Chief Medical Officer |
|
2019-02-01 |
4 |
D |
$21.00 |
$68,985 |
D/D |
(3,285) |
7,132 |
|
- |
|
Farzaneh-Far Ramin |
Chief Medical Officer |
|
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,417 |
10,417 |
|
- |
|
Treco Douglas A |
President and CEO |
|
2019-02-01 |
4 |
D |
$21.00 |
$132,867 |
D/D |
(6,327) |
218,799 |
|
- |
|
Treco Douglas A |
President and CEO |
|
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,834 |
225,126 |
|
- |
|
Read Simon |
Chief Scientific Officer |
|
2019-02-01 |
4 |
D |
$21.00 |
$61,593 |
D/D |
(2,933) |
6,234 |
|
- |
|
Read Simon |
Chief Scientific Officer |
|
2019-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,167 |
9,167 |
|
- |
|
Sandell Scott D |
10% Owner |
|
2018-12-14 |
4 |
B |
$15.50 |
$9,999,996 |
D/D |
645,161 |
6,135,234 |
2.45 |
- |
|
Shah Rajeev M. |
Director |
|
2018-12-14 |
4 |
B |
$15.50 |
$15,600,006 |
I/I |
1,006,452 |
4,858,260 |
2.25 |
- |
|
Kolchinsky Peter |
Director |
|
2018-12-12 |
4 |
B |
$15.50 |
$15,600,006 |
I/I |
1,006,452 |
4,858,260 |
2.25 |
- |
|
Viswanathan Ravi |
10% Owner |
|
2018-02-16 |
4 |
B |
$6.00 |
$12,000,000 |
D/D |
2,000,000 |
5,490,073 |
2.45 |
- |
|
Shah Rajeev M. |
Director |
|
2018-02-14 |
4 |
B |
$6.00 |
$15,000,000 |
I/I |
2,500,000 |
3,851,808 |
2.25 |
- |
|
Kolchinsky Peter |
10% Owner |
|
2018-02-14 |
4 |
B |
$6.00 |
$15,000,000 |
I/I |
2,500,000 |
3,851,808 |
1.5 |
- |
|
Novartis Ag |
10% Owner |
|
2017-06-19 |
4 |
S |
$22.02 |
$70,899 |
D/D |
(3,220) |
2,251,457 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-06-16 |
4 |
S |
$21.24 |
$1,130,207 |
D/D |
(53,200) |
2,254,677 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-06-08 |
4 |
S |
$22.00 |
$15,400 |
D/D |
(700) |
2,307,877 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-06-07 |
4 |
S |
$22.11 |
$106,999 |
D/D |
(4,840) |
2,308,577 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-06-06 |
4 |
S |
$22.98 |
$167,161 |
D/D |
(7,274) |
2,313,417 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-06-05 |
4 |
S |
$23.11 |
$110,488 |
D/D |
(4,780) |
2,320,691 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-06-02 |
4 |
S |
$23.47 |
$348,949 |
D/D |
(14,867) |
2,325,471 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-06-01 |
4 |
S |
$23.89 |
$256,176 |
D/D |
(10,722) |
2,340,338 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-05-31 |
4 |
S |
$23.94 |
$850,896 |
D/D |
(35,539) |
2,351,060 |
|
- |
|
148 Records found
|
|
Page 3 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|